Every material Form 8-K DaVita has filed with the SEC since August 06, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
DaVita Inc. announced consolidated revenues of $3.578 billion and diluted earnings per share of $3.40 for the third quarter ended September 30, 2026. The company also updated its full-year 2026 guidance ranges for adjusted operating income and adjusted diluted earnings per share.
Consolidated revenues for Q3 2026 were $3.578 billion with an operating income of $499 million.
Diluted earnings per share was $3.40 and adjusted diluted earnings per share was $3.82 for the quarter ended September 30, 2026.
The company repurchased 0.6 million shares for $111 million during the third quarter of 2026 at an average price of $186.21 per share.
Updated 2026 guidance projects adjusted operating income between $2.175 billion and $2.250 billion.
DaVita reported results for the quarter ended June 30, 2026, with total revenues of $3.554 billion, up from $3.380 billion a year earlier, and diluted earnings per share of $4.02, up from $2.58. Operating income rose to $579 million from $538 million, and the company reaffirmed its 2026 guidance ranges for adjusted operating income, adjusted diluted EPS, and free cash flow. The results show gains in revenue, operating income, and per-share profit for shareholders.
Total revenues were $3.554 billion, compared with $3.380 billion in the second quarter of 2025.
Diluted EPS was $4.02, compared with $2.58 a year earlier; operating income was $579 million, a 16.3% margin.
Current 2026 guidance: adjusted operating income of $2,150 million to $2,250 million and adjusted diluted EPS of $14.10 to $15.20.
During the quarter the company repurchased 2.2 million shares for $348 million and added a $500 million Term Loan B-2 tranche.
DaVita entered a Ninth Amendment to its credit agreement on June 8, 2026, providing a $500 million incremental term loan due May 2031. The company says it has used or will use the proceeds to repay part of its senior secured revolving loan, pay fees and expenses, and for general corporate purposes. At its June 4, 2026 annual meeting, stockholders elected all nine director nominees, ratified KPMG LLP as auditor, and approved executive compensation on an advisory basis.
$500 million incremental Tranche B-2 term loan, maturing May 2031, denominated in U.S. dollars
Interest at Term SOFR plus 175 basis points, or Base Rate plus 75 basis points, at the company's option
Proceeds to repay part of the senior secured revolving loan maturing November 2030, plus fees and general corporate purposes
Annual meeting on June 4, 2026: nine directors elected, KPMG LLP ratified, and say-on-pay approved; about 91% of shares represented
DaVita reported first-quarter 2026 revenue of $3.416 billion, up from $3.224 billion a year earlier, and operating income of $482 million, up from $439 million. It also raised its 2026 adjusted diluted EPS guidance to $14.10 to $15.20 from $13.60 to $15.00, which matters to shareholders because it signals higher expected profit for the year. Compared with the fourth quarter of 2025, revenue and operating income were lower.
Q1 2026 diluted EPS from continuing operations was $2.87, versus $2.00 in Q1 2025 and $2.94 in Q4 2025.
2026 adjusted operating income guidance rose to $2,150 million to $2,250 million from $2,085 million to $2,235 million.
Free cash flow guidance for 2026 was unchanged at $1,000 million to $1,250 million.
The company repurchased 3.0 million shares for $403 million in Q1 2026 and 2.0 million more shares for $302 million from April 1 through May 5, 2026.
DaVita reported fourth-quarter 2025 revenue of $3.620 billion, up from $3.295 billion a year earlier, while GAAP diluted EPS from continuing operations fell to $2.94 from $3.09 and operating income was $561 million versus $565 million. The company also issued 2026 guidance of $13.60 to $15.00 adjusted diluted EPS, $2.085 billion to $2.235 billion adjusted operating income, and $1.000 billion to $1.250 billion free cash flow, compared with 2025 adjusted diluted EPS of $10.78.
Q4 2025 consolidated revenue was $3.620 billion versus $3.295 billion in Q4 2024; operating income was $561 million versus $565 million.
Q4 2025 diluted EPS from continuing operations was $2.94 (Q4 2024: $3.09); adjusted diluted EPS was $3.40 (Q3 2025: $2.51).
2026 guidance: adjusted operating income of $2,085 million to $2,235 million and adjusted diluted EPS of $13.60 to $15.00.
Repurchased 2.7 million shares for $331 million in Q4 2025, and 1.7 million shares for $200 million from January 1 through February 2, 2026.
On November 24, 2025, DaVita entered an Eighth Amendment to its 2019 Credit Agreement, providing new five-year secured facilities of up to $2 billion in term loan A and $1.5 billion in revolving credit to refinance its prior facilities maturing in April 2028. The filing states proceeds will repay the prior facilities, cover fees and expenses, and fund working capital and general corporate purposes, which may include stock repurchases, acquisitions and investments.
New A-2 term loan facility of up to $2 billion and new revolving facility of up to $1.5 billion, both five years
Refinances a prior term loan of approximately $1.950 billion and a prior $1.5 billion revolver, both maturing April 2028
Initial margin of 150 basis points over Term SOFR; margin and revolver commitment fee move to a leverage-based grid after financial statements for the quarter ending March 31, 2026
Term loan amortizes quarterly from March 31, 2026, at 2.5% per year for two years, then 5.0% per year
DaVita reported third-quarter 2025 results with total revenues of $3.420 billion, up from $3.264 billion a year earlier, while net income attributable to DaVita fell to $150 million from $215 million and diluted EPS fell to $2.04 from $2.50. The company narrowed its 2025 adjusted operating income and adjusted diluted EPS guidance and kept free cash flow guidance at $1.0 billion to $1.25 billion, and it repurchased $465 million of stock in the quarter.
Q3 2025 total revenues were $3.420 billion versus $3.264 billion in Q3 2024; operating income was $506 million versus $535 million.
Adjusted diluted EPS guidance narrowed to $10.35 to $11.15 from $10.20 to $11.30; adjusted operating income guidance narrowed to $2,035 million to $2,135 million from $2,010 million to $2,160 million.
Cybersecurity incident charges of approximately $11.7 million were recorded in Q3 2025 in general and administrative expenses and are excluded from adjusted metrics.
The company repurchased 3.3 million shares for $465 million in Q3 2025 and an additional 0.4 million shares for $54 million from October 1 through October 28, 2025.
DaVita reported second-quarter 2025 results with revenue of $3.380 billion, up from $3.187 billion a year earlier. Net income attributable to DaVita fell to $199 million from $223 million, while diluted earnings per share rose to $2.58 from $2.50, helped by a lower share count. The company also issued $1.0 billion of 6.75% senior notes and repurchased 3.1 million shares for $446 million.
Q2 2025 revenue was $3.380 billion versus $3.187 billion in Q2 2024; operating income was $538 million versus $506 million.
Diluted EPS was $2.58 (adjusted $2.95) versus $2.50 a year earlier; net income attributable to DaVita was $199 million versus $223 million.
Cybersecurity incident charges were about $13.5 million in the quarter, and debt expense rose to $146 million from $98 million.
DaVita entered a Seventh Amendment to its Credit Agreement with Wells Fargo as administrative agent, repricing its senior secured term loan B facility maturing in May 2031 and adding $250 million of incremental term loans. The company used the proceeds to repay $250 million of senior secured term A loans maturing in April 2028. The filing does not report a change in total debt outstanding or a change in the company's financial results.
Seventh Amendment dated July 17, 2025 reprices the term loan B facility, now the Tranche B-2 Term Facility, maturing May 2031.
Applicable margin is 175 basis points for Term SOFR loans and 75 basis points for Base Rate loans, down from 200 and 100 basis points.
Incremental $250 million of Tranche B-2 Term Loans used to repay $250 million of term A loans maturing April 2028.
Wells Fargo Bank, National Association serves as administrative agent, collateral agent and swingline lender.
DaVita completed a $1.0 billion private offering of 6.750% senior notes due July 15, 2033, with net proceeds of approximately $986 million. The company plans to use $830 million to repay revolving credit facility borrowings, with the remainder for general corporate purposes, including stock repurchases, working capital and capital expenditures.
Offering size: $1.0 billion aggregate principal of 6.750% Senior Notes due 2033, closed May 23, 2025
Approximately $986 million in net proceeds after initial purchasers' discount and fees
$830 million of proceeds earmarked to repay outstanding revolving credit facility borrowings
Notes are unsecured, rank equally with other senior debt, and are not listed on any securities exchange
DaVita reported first-quarter 2025 results for the period ended March 31, 2025. Revenue rose from $3.071 billion a year earlier, but operating income fell to $439 million from $484 million and diluted EPS fell to $2.00 from $2.65. The company also reaffirmed 2025 guidance of $10.20 to $11.30 in adjusted diluted EPS and $1.0 billion to $1.25 billion in free cash flow, and repurchased 3.7 million shares for $550 million during the quarter.
Total consolidated revenues were $3.224 billion, up from $3.071 billion in the first quarter of 2024.
Operating income was $439 million, a 13.6% margin, compared with $484 million and a 15.8% margin a year earlier.
Diluted EPS was $2.00, compared with $2.65; adjusted diluted EPS was $2.00, compared with $2.26.
2025 guidance: adjusted operating income $2.010 billion to $2.160 billion; free cash flow $1.000 billion to $1.250 billion.
DaVita reported fourth-quarter 2024 revenue of $3.295 billion, up from $3.146 billion a year earlier, and diluted EPS of $3.09 versus $1.62. Adjusted diluted EPS was $2.24, down from $2.59 in the third quarter of 2024, and the company gave 2025 adjusted diluted EPS guidance of $10.20 to $11.30. The gain on changes in ownership interests contributed to the GAAP results, and shareholders benefit from the company's continued share repurchases.
Q4 2024 revenue was $3.295 billion, compared with $3.146 billion in Q4 2023.
Q4 2024 diluted EPS was $3.09, compared with $1.62 a year earlier; adjusted diluted EPS was $2.24, versus $2.59 in Q3 2024.
Full-year 2024 adjusted diluted EPS was $9.68, up from $7.67 in 2023.
2025 guidance: adjusted operating income of $2.010 billion to $2.160 billion and free cash flow of $1.000 billion to $1.250 billion.
DaVita reported third-quarter 2024 results. Revenue rose to $3.264 billion from $3.121 billion a year earlier and operating income rose to $535 million, but diluted EPS fell to $2.50 from $2.62 and net income attributable to DaVita fell to $215 million from $247 million. The company kept its 2024 adjusted guidance, which now includes center closure costs, and reported $406 million of share repurchases in the quarter.
Total revenues were $3.264 billion for the quarter ended September 30, 2024, versus $3.121 billion in the same quarter of 2023.
Diluted EPS was $2.50 versus $2.62 a year earlier; adjusted diluted EPS was $2.59.
2024 guidance: adjusted operating income of $1.91 billion to $2.01 billion, adjusted diluted EPS of $9.25 to $10.05, and free cash flow of $950 million to $1.2 billion.
The company repurchased 2.7 million shares for $406 million in the third quarter.
DaVita appointed Senior Vice President David P. Maughan as Chief Operating Officer, DaVita Kidney Care, effective September 15, 2024, replacing Michael D. Staffieri, who moves to Chief Operating Officer Emeritus. The company also entered an employment agreement with Maughan with a $725,000 base salary and a 2024 target bonus of 100% of base salary.
David P. Maughan, 47, succeeds Michael D. Staffieri as COO, DaVita Kidney Care, effective September 15, 2024
Maughan joined DaVita in 2006 and most recently served as Senior Vice President, Kidney Care, from November 2019 to September 2024
Employment agreement sets annual base salary of $725,000 and a 2024 target incentive bonus equal to 100% of base salary
Severance includes at least one year of base salary continuation on resignation for good cause, or two years within 60 days after a good-cause event following a change in control
DaVita completed a $1.0 billion private offering of 6.875% senior notes due 2032 on August 13, 2024, and entered into a credit agreement amendment adding a $1.1 billion incremental term loan maturing April 28, 2028. The company said net proceeds of about $2,080.7 million were used to repay roughly $950.0 million of Tranche B-1 term loans and $60.0 million of revolving loans, with $350.0 million more of revolving loans planned for repayment. The refinancing changes the company's debt mix and interest costs, but the filing does not state the effect on total debt.
$1.0 billion of 6.875% senior notes due September 1, 2032, issued in a private offering completed August 13, 2024
$1.1 billion incremental Term Loan A-1 facility maturing April 28, 2028, with quarterly amortization starting September 30, 2024
Net proceeds of about $2,080.7 million used to repay roughly $950.0 million of 2026 term loans and $60.0 million of revolving loans
Remaining proceeds planned for $350.0 million of revolving loan repayment and general corporate purposes, including possible share repurchases
DaVita reported second-quarter 2024 revenue of $3.187 billion, up from $3.000 billion a year earlier, and diluted EPS of $2.50 versus $1.91. The company raised its 2024 adjusted diluted EPS guidance to $9.25-$10.05 from $9.00-$9.80, though the filing notes that the change reflects a new presentation that no longer excludes about $60 million in center closure costs.
Q2 2024 total revenues were $3.187 billion versus $3.000 billion in Q2 2023; operating income was $506 million versus $405 million.
Diluted EPS was $2.50 versus $1.91 a year earlier; adjusted diluted EPS was $2.59 versus $2.26 in the first quarter of 2024.
Current 2024 adjusted diluted EPS guidance is $9.25 to $10.05, compared with prior guidance of $9.00 to $9.80 given as of May 2, 2024.
During Q2 2024 the company repurchased 2.7 million shares for $376 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every DaVita filing is on SEC EDGAR ↗. 8-K briefs of other companies →